Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

E Furst

Showing results (451-460 of 755) with videos related to

Pageof 76
Sort By:
The Journal of Rheumatology|April 1, 1987
A strategy for reaching therapeutic salicylate levels in patients with rheumatoid arthritis using standardized dosing regimensD E Furst, K Blocka, S Cassell, et al.
Annals of the Rheumatic Diseases|March 14, 2002
Updated consensus statement on tumour necrosis factor blocking agents for the treatment of rheumatoid arthritis and other rheumatic diseases (April 2001)D E Furst, E C Keystone, F C Breedveld, et al.
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research|January 24, 2012
Feasibility and construct validity of PROMIS and "legacy" instruments in an academic scleroderma clinicDinesh Khanna, Paul Maranian, Nan Rothrock, et al.
Clinical and Experimental Rheumatology|March 2, 2023
Application of logistic regression and machine learning methods for idiopathic inflammatory myopathies malignancy predictionWeijin Zhang, Guohai Huang, Kedi Zheng, et al.
Annals of the Rheumatic Diseases|August 26, 2010
Well controlled, double-blind, placebo-controlled trials of classical Ayurvedic treatment are possible in rheumatoid arthritisDaniel E Furst, Manorama M Venkatraman, B G Krishna Swamy, et al.
Quality of Life Research : an International Journal of Quality of Life Aspects of Treatment, Care and Rehabilitation|April 4, 2007
Reliability, validity, and minimally important differences of the SF-6D in systemic sclerosisDinesh Khanna, Daniel E Furst, Weng Kee Wong, et al.
JAMA|May 11, 2016
Effect of Macitentan on the Development of New Ischemic Digital Ulcers in Patients With Systemic Sclerosis: DUAL-1 and DUAL-2 Randomized Clinical TrialsDinesh Khanna, Christopher P Denton, Peter A Merkel, et al.
Arthritis and Rheumatism|April 9, 2005
Evidence of radiographic benefit of treatment with infliximab plus methotrexate in rheumatoid arthritis patients who had no clinical improvement: a detailed subanalysis of data from the anti-tumor necrosis factor trial in rheumatoid arthritis with concomitant therapy studyJ S Smolen, C Han, M Bala, et al.
Nutrients|January 10, 2017
Marine Oil Supplements for Arthritis Pain: A Systematic Review and Meta-Analysis of Randomized TrialsNinna K Senftleber, Sabrina M Nielsen, Jens R Andersen, et al.
Annals of the Rheumatic Diseases|November 5, 2014
Evaluating drug-free remission with abatacept in early rheumatoid arthritis: results from the phase 3b, multicentre, randomised, active-controlled AVERT study of 24 months, with a 12-month, double-blind treatment periodPaul Emery, Gerd R Burmester, Vivian P Bykerk, et al.
Pageof 76

Showing results (451-460 of 755) with videos related to

Sort By:
Pageof 76
The Journal of Rheumatology|April 1, 1987
A strategy for reaching therapeutic salicylate levels in patients with rheumatoid arthritis using standardized dosing regimensD E Furst, K Blocka, S Cassell, et al.
Annals of the Rheumatic Diseases|March 14, 2002
Updated consensus statement on tumour necrosis factor blocking agents for the treatment of rheumatoid arthritis and other rheumatic diseases (April 2001)D E Furst, E C Keystone, F C Breedveld, et al.
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research|January 24, 2012
Feasibility and construct validity of PROMIS and "legacy" instruments in an academic scleroderma clinicDinesh Khanna, Paul Maranian, Nan Rothrock, et al.
Clinical and Experimental Rheumatology|March 2, 2023
Application of logistic regression and machine learning methods for idiopathic inflammatory myopathies malignancy predictionWeijin Zhang, Guohai Huang, Kedi Zheng, et al.
Annals of the Rheumatic Diseases|August 26, 2010
Well controlled, double-blind, placebo-controlled trials of classical Ayurvedic treatment are possible in rheumatoid arthritisDaniel E Furst, Manorama M Venkatraman, B G Krishna Swamy, et al.
Quality of Life Research : an International Journal of Quality of Life Aspects of Treatment, Care and Rehabilitation|April 4, 2007
Reliability, validity, and minimally important differences of the SF-6D in systemic sclerosisDinesh Khanna, Daniel E Furst, Weng Kee Wong, et al.
JAMA|May 11, 2016
Effect of Macitentan on the Development of New Ischemic Digital Ulcers in Patients With Systemic Sclerosis: DUAL-1 and DUAL-2 Randomized Clinical TrialsDinesh Khanna, Christopher P Denton, Peter A Merkel, et al.
Arthritis and Rheumatism|April 9, 2005
Evidence of radiographic benefit of treatment with infliximab plus methotrexate in rheumatoid arthritis patients who had no clinical improvement: a detailed subanalysis of data from the anti-tumor necrosis factor trial in rheumatoid arthritis with concomitant therapy studyJ S Smolen, C Han, M Bala, et al.
Nutrients|January 10, 2017
Marine Oil Supplements for Arthritis Pain: A Systematic Review and Meta-Analysis of Randomized TrialsNinna K Senftleber, Sabrina M Nielsen, Jens R Andersen, et al.
Annals of the Rheumatic Diseases|November 5, 2014
Evaluating drug-free remission with abatacept in early rheumatoid arthritis: results from the phase 3b, multicentre, randomised, active-controlled AVERT study of 24 months, with a 12-month, double-blind treatment periodPaul Emery, Gerd R Burmester, Vivian P Bykerk, et al.
Pageof 76